FADD Polyclonal Antibody
- Known as:
- FADD Polyclonal Antibody
- Catalog number:
- a-0444-200
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Epigentek inc
- Gene target:
- FADD Polyclonal Antibody
Related genes to: FADD Polyclonal Antibody
- Gene:
- FADD NIH gene
- Name:
- Fas associated via death domain
- Previous symbol:
- -
- Synonyms:
- MORT1, GIG3
- Chromosome:
- 11q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-05-07
- Date modifiied:
- 2019-04-23
Related products to: FADD Polyclonal Antibody
Related articles to: FADD Polyclonal Antibody
- The generation of isogenic knockout (KO) cell lines for intracellular proteins using non-viral CRISPR-Cas9 approaches has long been technically demanding and time-consuming. Here, we describe a streamlined and cost-effective method based on ptARgenOM, an all-in-one mammalian expression vector designed for efficient delivery of the CRISPR-Cas9 system. This vector co-expresses the guide RNA (gRNA) and Cas9 endonuclease, which is fused to a ribosomal skipping peptide sequence followed by the enhanced green fluorescent protein (EGFP) and the puromycin N-acetyltransferase. This design enables transient, expression-dependent antibiotic selection and fluorescence-based enrichment of successfully transfected cells, facilitating the rapid generation of isogenic KO populations or clones. The method is particularly well-suited, though not limited, to functional studies involving intracellular components of the cell death machinery, including both the extrinsic and intrinsic apoptotic signaling pathways. We illustrate the utility of this system by targeting and deleting FADD, Caspase-8, and RIPK1. This approach can be easily adapted to any intracellular target protein, offering a robust platform for gene function analysis in mammalian cells. - Source: PubMed
Publication date: 2026/03/09
Radoua AbdelmnimAlrustom BacharWang JiaJiaBordessoules MorganeChluba JohannaPlenchette StéphanieMicheau Olivier - Oral squamous cell carcinoma (OSCC) remains a clinical challenge with limited prognostic tools. This study aimed to identify a novel autophagy-related gene signature for precise prognosis prediction and to elucidate its potential clinical utility in guiding risk stratification and personalized treatment strategies for OSCC patients. - Source: PubMed
Publication date: 2026/06/11
Zhang YinanGao HongyuFan YongjingWang DanFan ShuangshuangLi HuijieWang Shu - Extrachromosomal DNA (ecDNA) drives oncogene amplification and transcriptional rewiring in many cancers. For head‑and‑neck squamous cell carcinoma (HNSCC), the prevalence of ecDNA has been reported on the top across various cancer types. However, the clinical significance of ecDNA remain incompletely defined. This study aimed to (1) systematically evaluate ecDNA frequency and architecture in HNSCC, (2) examine its associations with clinical characteristics, and (3) identify driver oncogenes amplified by ecDNA, if any, that might impact patient prognosis. - Source: PubMed
Publication date: 2026/06/10
Tsou PeilingWu Chang-Jiun - Geographic variability in the clinical efficacy of tonsillectomy for immunoglobulin A nephropathy (IgAN) suggests population-level differences in mucosal immune architecture. However, the molecular features of the tonsillar germinal center (GC) microenvironment-the central site for IgA class switching and mucosal B-cell activation-remain poorly characterized, particularly in relation to glomerular injury severity. - Source: PubMed
Publication date: 2026/05/22
Kawabe MayukoYamamoto IzumiOhki YutaroHayashi AyakaKanzaki GoMatsumoto KeiUeda HiroyukiHirano KeitaTsuboi NobuoYokoo Takashi - Head and neck squamous cell carcinoma (HNSCC) was characterized by pronounced heterogeneity and therapeutic resistance, which posed challenges for effective clinical management. Regulated cell death (RCD) and cellular senescence (CS) were recognized as fundamental hallmarks of cancer, exerting effects on tumorigenesis, progression, and treatment sensitivity. However, the utility of cell death and cellular senescence (CDCS) in predicting prognosis and therapeutic response had not been fully established. - Source: PubMed
Publication date: 2026/05/22
Luo XiaoqinHe Xian